Loading...

Kathleen Lamborn, PhD

TitleNON-SENATE ACAD EMERITUS(WOS)
InstitutionUniversity of California San Francisco
DepartmentNeurological Surgery
Address550 16th Street
San Francisco CA 94158
Phone415-353-2863
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    SPORE: Brain Tumore SPORE Grant
    NIH/NCI P50CA097257Sep 20, 2002 - Aug 31, 2018
    Role: Co-Investigator
    Cancer Center Support Grant
    NIH/NCI P30CA082103Aug 5, 1999 - May 31, 2018
    Role: Co-Investigator
    Translational Multimodality " Antibody" Therapy
    NIH P01CA047829Jul 15, 1988 - Mar 31, 2009
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Wen PY, Chang SM, Lamborn K, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S, Ligon AH, Yung WK, Wright JJ, Dancey J, Aldape KD, Prados MD, Ligon KL. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro Oncol. 2014 Apr; 16(4):567-78. PMID: 24470557; PMCID: PMC3956354.
    2. Lin NU, Lee EQ, Aoyama H, Barani IJ, Baumert BG, Brown PD, Camidge DR, Chang SM, Dancey J, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Lamborn K, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wefel JS, Wen PY. Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncol. 2013 Sep; 14(10):e396-406. PMID: 23993384.
      View in: PubMed
    3. Hensley-Judge H, Quigg M, Barbaro NM, Newman SA, Ward MM, Chang EF, Broshek DK, Lamborn K, Laxer KD, Garcia P, Heck CN, Kondziolka D, Beach R, Salanova V, Goodman R. Visual field defects after radiosurgery for mesial temporal lobe epilepsy. Epilepsia. 2013 Aug; 54(8):1376-80. PMID: 23663063.
      View in: PubMed
    4. Li Y, Lupo JM, Parvataneni R, Lamborn K, Cha S, Chang SM, Nelson SJ. Survival analysis in patients with newly diagnosed glioblastoma using pre- and postradiotherapy MR spectroscopic imaging. Neuro Oncol. 2013 May; 15(5):607-17. PMID: 23393206; PMCID: PMC3635514.
    5. Lee EQ, Kuhn J, Lamborn K, Abrey L, DeAngelis LM, Lieberman F, Robins HI, Chang SM, Yung WK, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados MD, Cloughesy TF, Gilbert MR, Wen PY. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro Oncol. 2012 Dec; 14(12):1511-8. PMID: 23099651; PMCID: PMC3499017.
    6. Lee EQ, Puduvalli VK, Reid JM, Kuhn JG, Lamborn K, Cloughesy TF, Chang SM, Drappatz J, Yung WK, Gilbert MR, Robins HI, Lieberman FS, Lassman AB, McGovern RM, Xu J, Desideri S, Ye X, Ames MM, Espinoza-Delgado I, Prados MD, Wen PY. Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. Clin Cancer Res. 2012 Nov 01; 18(21):6032-9. PMID: 22923449; PMCID: PMC3947570.
    7. Galanis E, Wu W, Cloughesy T, Lamborn K, Mann B, Wen PY, Reardon DA, Wick W, Macdonald D, Armstrong TS, Weller M, Vogelbaum M, Colman H, Sargent DJ, van den Bent MJ, Gilbert M, Chang S. Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. Lancet Oncol. 2012 May; 13(5):e196-204. PMID: 22554547.
      View in: PubMed
    8. Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N, Tao H, Zhu S, Iwanami A, Kuga D, Dang J, Pedraza A, Brennan CW, Heguy A, Liau LM, Lieberman F, Yung WK, Gilbert MR, Reardon DA, Drappatz J, Wen PY, Lamborn K, Chang SM, Prados MD, Fine HA, Horvath S, Wu N, Lassman AB, DeAngelis LM, Yong WH, Kuhn JG, Mischel PS, Mehta MP, Cloughesy TF, Mellinghoff IK. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2012 May; 2(5):458-71. PMID: 22588883; PMCID: PMC3354723.
    9. Schoenfeld A, Pekmezci M, Barnes MJ, Tihan T, Gupta N, Lamborn K, Banerjee A, Mueller S, Chang S, Berger MS, Haas-Kogan D. The superiority of conservative resection and adjuvant radiation for craniopharyngiomas. J Neurooncol. 2012 May; 108(1):133-9. PMID: 22350375; PMCID: PMC3879154.
    10. Clark AJ, Lamborn K, Butowski NA, Chang SM, Prados MD, Clarke JL, McDermott MW, Parsa AT, Berger MS, Aghi MK. Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment. Neurosurgery. 2012 Feb; 70(2):361-70. PMID: 21841523.
      View in: PubMed
    11. Ozturk-Isik E, Pirzkall A, Lamborn K, Cha S, Chang SM, Nelson SJ. Spatial characteristics of newly diagnosed grade 3 glioma assessed by magnetic resonance metabolic and diffusion tensor imaging. Transl Oncol. 2012 Feb; 5(1):10-8. PMID: 22348171; PMCID: PMC3281410.
    12. Caballero JA, Sneed PK, Lamborn K, Ma L, Denduluri S, Nakamura JL, Barani IJ, McDermott MW. Prognostic factors for survival in patients treated with stereotactic radiosurgery for recurrent brain metastases after prior whole brain radiotherapy. Int J Radiat Oncol Biol Phys. 2012 May 01; 83(1):303-9. PMID: 22079723.
      View in: PubMed
    13. Potts MB, Jahangiri A, Lamborn K, Blevins LS, Kunwar S, Aghi MK. Suprasellar Rathke cleft cysts: clinical presentation and treatment outcomes. Neurosurgery. 2011 Nov; 69(5):1058-68; discussion 1068-7. PMID: 21673610.
      View in: PubMed
    14. Polley MY, Lamborn K, Chang SM, Butowski N, Clarke JL, Prados M. Conditional probability of survival in patients with newly diagnosed glioblastoma. J Clin Oncol. 2011 Nov 01; 29(31):4175-80. PMID: 21969507; PMCID: PMC3208537.
    15. Butowski N, Chang SM, Lamborn K, Polley MY, Pieper R, Costello JF, Vandenberg S, Parvataneni R, Nicole A, Sneed PK, Clarke J, Hsieh E, Costa BM, Reis RM, Hristova-Kazmierski M, Nicol SJ, Thornton DE, Prados MD. Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Neuro Oncol. 2011 Dec; 13(12):1331-8. PMID: 21896554; PMCID: PMC3223090.
    16. Clarke JL, Ennis MM, Yung WK, Chang SM, Wen PY, Cloughesy TF, Deangelis LM, Robins HI, Lieberman FS, Fine HA, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Lamborn K, Prados MD. Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro Oncol. 2011 Oct; 13(10):1118-24. PMID: 21813511; PMCID: PMC3177665.
    17. Gilbert MR, Kuhn J, Lamborn K, Lieberman F, Wen PY, Mehta M, Cloughesy T, Lassman AB, Deangelis LM, Chang S, Prados M. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. J Neurooncol. 2012 Jan; 106(1):147-53. PMID: 21739168; PMCID: PMC4351869.
    18. Jahangiri A, Lamborn K, Blevins L, Kunwar S, Aghi MK. Factors associated with delay to pituitary adenoma diagnosis in patients with visual loss. J Neurosurg. 2012 Feb; 116(2):283-9. PMID: 21740118.
      View in: PubMed
    19. de Groot JF, Lamborn K, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, Yao J, Jackson EF, Lieberman F, Robins HI, Mehta MP, Lassman AB, Deangelis LM, Yung WK, Chen A, Prados MD, Wen PY. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol. 2011 Jul 01; 29(19):2689-95. PMID: 21606416; PMCID: PMC3139373.
    20. Quigg M, Broshek DK, Barbaro NM, Ward MM, Laxer KD, Yan G, Lamborn K. Neuropsychological outcomes after Gamma Knife radiosurgery for mesial temporal lobe epilepsy: a prospective multicenter study. Epilepsia. 2011 May; 52(5):909-16. PMID: 21426323; PMCID: PMC3519361.
    21. Iwamoto FM, Lamborn K, Kuhn JG, Wen PY, Yung WK, Gilbert MR, Chang SM, Lieberman FS, Prados MD, Fine HA. A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro Oncol. 2011 May; 13(5):509-16. PMID: 21377994; PMCID: PMC3093337.
    22. Parvataneni R, Polley MY, Freeman T, Lamborn K, Prados M, Butowski N, Liu R, Clarke J, Page M, Rabbitt J, Fedoroff A, Clow E, Hsieh E, Kivett V, Deboer R, Chang S. Identifying the needs of brain tumor patients and their caregivers. J Neurooncol. 2011 Sep; 104(3):737-44. PMID: 21311950; PMCID: PMC3170122.
    23. Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn K, Lassman AB, Gilbert MR, Sampson JH, Wick W, Chamberlain MC, Macdonald DR, Mehta MP, Vogelbaum MA, Chang SM, Van den Bent MJ, Wen PY. Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol. 2011 Mar; 13(3):353-61. PMID: 21310734; PMCID: PMC3064608.
    24. Nghiemphu PL, Wen PY, Lamborn K, Drappatz J, Robins HI, Fink K, Malkin MG, Lieberman FS, DeAngelis LM, Torres-Trejo A, Chang SM, Abrey L, Fine HA, Demopoulos A, Lassman AB, Kesari S, Mehta MP, Prados MD, Cloughesy TF. A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys. 2011 Dec 01; 81(5):1422-7. PMID: 20934264; PMCID: PMC3020272.
    25. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn K, Vogelbaum MA, van den Bent MJ, Chang SM. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010 Apr 10; 28(11):1963-72. PMID: 20231676.
      View in: PubMed
    26. Mishra KK, Squire S, Lamborn K, Banerjee A, Gupta N, Wara WM, Prados MD, Berger MS, Haas-Kogan DA. Phase II TPDCV protocol for pediatric low-grade hypothalamic/chiasmatic gliomas: 15-year update. J Neurooncol. 2010 Oct; 100(1):121-7. PMID: 20221671; PMCID: PMC2951507.
    27. Iwamoto FM, Lamborn K, Robins HI, Mehta MP, Chang SM, Butowski NA, Deangelis LM, Abrey LE, Zhang WT, Prados MD, Fine HA. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol. 2010 Aug; 12(8):855-61. PMID: 20200024; PMCID: PMC2940686.
    28. Butowski N, Chang SM, Lamborn K, Polley MY, Parvataneni R, Hristova-Kazmierski M, Musib L, Nicol SJ, Thornton DE, Prados MD. Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study. Neuro Oncol. 2010 Jun; 12(6):608-13. PMID: 20156802; PMCID: PMC2940647.
    29. Wu W, Lamborn K, Buckner JC, Novotny PJ, Chang SM, O'Fallon JR, Jaeckle KA, Prados MD. Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma. Neuro Oncol. 2010 Feb; 12(2):164-72. PMID: 20150383; PMCID: PMC2940570.
    30. Polley MY, Lamborn K, Chang SM, Butowski N, Clarke JL, Prados M. Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide. Neuro Oncol. 2010 Mar; 12(3):274-82. PMID: 20167815; PMCID: PMC2940590.
    31. Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn K, Kuhn JG, Yung WK, Gilbert MR, Aldape KD, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, Prados MD. A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro Oncol. 2010 Jan; 12(1):87-94. PMID: 20150371; PMCID: PMC2940559.
    32. Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn K, Kuhn JG, Yung WK, Gilbert MR, Aldape KA, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, Prados MD. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol. 2010 Jan; 12(1):95-103. PMID: 20150372; PMCID: PMC2940554.
    33. Pirzkall A, McGue C, Saraswathy S, Cha S, Liu R, Vandenberg S, Lamborn K, Berger MS, Chang SM, Nelson SJ. Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma. Neuro Oncol. 2009 Dec; 11(6):842-52. PMID: 19229057; PMCID: PMC2802404.
    34. Wen PY, Yung WK, Lamborn K, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, Ligon KL, Aldape K, Jain RK, Stiles CD, Egorin MJ, Prados MD. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol. 2009 Dec; 11(6):853-60. PMID: 19293394; PMCID: PMC2802405.
    35. Bian W, Khayal IS, Lupo JM, McGue C, Vandenberg S, Lamborn K, Chang SM, Cha S, Nelson SJ. Multiparametric characterization of grade 2 glioma subtypes using magnetic resonance spectroscopic, perfusion, and diffusion imaging. Transl Oncol. 2009 Dec; 2(4):271-80. PMID: 19956389; PMCID: PMC2781083.
    36. McBride SM, Perez DA, Polley MY, Vandenberg SR, Smith JS, Zheng S, Lamborn K, Wiencke JK, Chang SM, Prados MD, Berger MS, Stokoe D, Haas-Kogan DA. Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival. J Neurooncol. 2010 Mar; 97(1):33-40. PMID: 19705067; PMCID: PMC2814032.
    37. Fishman K, Baure J, Zou Y, Huang TT, Andres-Mach M, Rola R, Suarez T, Acharya M, Limoli CL, Lamborn K, Fike JR. Radiation-induced reductions in neurogenesis are ameliorated in mice deficient in CuZnSOD or MnSOD. Free Radic Biol Med. 2009 Nov 15; 47(10):1459-67. PMID: 19703553; PMCID: PMC2767469.
    38. Norden AD, Raizer JJ, Abrey LE, Lamborn K, Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, Deangelis LM, Cloughesy TF, Robins HI, Aldape K, Dancey J, Prados MD, Lieberman F, Wen PY. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol. 2010 Jan; 96(2):211-7. PMID: 19562255; PMCID: PMC3786190.
    39. Cage TA, Lamborn K, Ware ML, Frankfurt A, Chakalian L, Berger MS, McDermott MW. Adjuvant enoxaparin therapy may decrease the incidence of postoperative thrombotic events though does not increase the incidence of postoperative intracranial hemorrhage in patients with meningiomas. J Neurooncol. 2009 May; 93(1):151-6. PMID: 19430892.
      View in: PubMed
    40. Khayal IS, McKnight TR, McGue C, Vandenberg S, Lamborn K, Chang SM, Cha S, Nelson SJ. Apparent diffusion coefficient and fractional anisotropy of newly diagnosed grade II gliomas. NMR Biomed. 2009 May; 22(4):449-55. PMID: 19125391; PMCID: PMC3772178.
    41. Barbaro NM, Quigg M, Broshek DK, Ward MM, Lamborn K, Laxer KD, Larson DA, Dillon W, Verhey L, Garcia P, Steiner L, Heck C, Kondziolka D, Beach R, Olivero W, Witt TC, Salanova V, Goodman R. A multicenter, prospective pilot study of gamma knife radiosurgery for mesial temporal lobe epilepsy: seizure response, adverse events, and verbal memory. Ann Neurol. 2009 Feb; 65(2):167-75. PMID: 19243009.
      View in: PubMed
    42. Lim DA, Tarapore P, Chang E, Burt M, Chakalian L, Barbaro N, Chang S, Lamborn K, McDermott MW. Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study. J Neurooncol. 2009 Jul; 93(3):349-54. PMID: 19169651; PMCID: PMC2687520.
    43. Prados MD, Chang SM, Butowski N, DeBoer R, Parvataneni R, Carliner H, Kabuubi P, Ayers-Ringler J, Rabbitt J, Page M, Fedoroff A, Sneed PK, Berger MS, McDermott MW, Parsa AT, Vandenberg S, James CD, Lamborn K, Stokoe D, Haas-Kogan DA. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol. 2009 Feb 01; 27(4):579-84. PMID: 19075262; PMCID: PMC2645859.
    44. Golden DW, Lamborn K, McDermott MW, Kunwar S, Wara WM, Nakamura JL, Sneed PK. Prognostic factors and grading systems for overall survival in patients treated with radiosurgery for brain metastases: variation by primary site. J Neurosurg. 2008 Dec; 109 Suppl:77-86. PMID: 19123892.
      View in: PubMed
    45. Crawford FW, Khayal IS, McGue C, Saraswathy S, Pirzkall A, Cha S, Lamborn K, Chang SM, Berger MS, Nelson SJ. Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM. J Neurooncol. 2009 Feb; 91(3):337-51. PMID: 19009235; PMCID: PMC3022444.
    46. Chang EF, Smith JS, Chang SM, Lamborn K, Prados MD, Butowski N, Barbaro NM, Parsa AT, Berger MS, McDermott MM. Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. J Neurosurg. 2008 Nov; 109(5):817-24. PMID: 18976070.
      View in: PubMed
    47. Butowski N, Lamborn K, Lee BL, Prados MD, Cloughesy T, DeAngelis LM, Abrey L, Fink K, Lieberman F, Mehta M, Ian Robins H, Junck L, Salazar AM, Chang SM. A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J Neurooncol. 2009 Jan; 91(2):183-9. PMID: 18850068; PMCID: PMC3104130.
    48. Saraswathy S, Crawford FW, Lamborn K, Pirzkall A, Chang S, Cha S, Nelson SJ. Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy. J Neurooncol. 2009 Jan; 91(1):69-81. PMID: 18810326; PMCID: PMC3022437.
    49. Butowski N, Chang SM, Junck L, DeAngelis LM, Abrey L, Fink K, Cloughesy T, Lamborn K, Salazar AM, Prados MD. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). J Neurooncol. 2009 Jan; 91(2):175-82. PMID: 18797818; PMCID: PMC4779120.
    50. Ermoian RP, Kaprealian T, Lamborn K, Yang X, Jelluma N, Arvold ND, Zeidman R, Berger MS, Stokoe D, Haas-Kogan DA. Signal transduction molecules in gliomas of all grades. J Neurooncol. 2009 Jan; 91(1):19-26. PMID: 18759130; PMCID: PMC2879130.
    51. Meyers CA, Lamborn K, Prados MD. In reference to lamborn et Al. (Neuro-oncology. 2008;10:162-170). Neuro Oncol. 2008 Dec; 10(6):1171-2. PMID: 18725461; PMCID: PMC2719004.
    52. Liu R, Solheim K, Polley MY, Lamborn K, Page M, Fedoroff A, Rabbitt J, Butowski N, Prados M, Chang SM. Quality of life in low-grade glioma patients receiving temozolomide. Neuro Oncol. 2009 Feb; 11(1):59-68. PMID: 18713953; PMCID: PMC2718960.
    53. Chang SM, Lamborn K, Kuhn JG, Yung WK, Gilbert MR, Wen PY, Fine HA, Mehta MP, DeAngelis LM, Lieberman FS, Cloughesy TF, Robins HI, Abrey LE, Prados MD. Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. Neuro Oncol. 2008 Aug; 10(4):631-42. PMID: 18559968; PMCID: PMC2666238.
    54. Rola R, Fishman K, Baure J, Rosi S, Lamborn K, Obenaus A, Nelson GA, Fike JR. Hippocampal neurogenesis and neuroinflammation after cranial irradiation with (56)Fe particles. Radiat Res. 2008 Jun; 169(6):626-32. PMID: 18494546; PMCID: PMC2583781.
    55. McBride SM, Daganzo SM, Banerjee A, Gupta N, Lamborn K, Prados MD, Berger MS, Wara WM, Haas-Kogan DA. Radiation is an important component of multimodality therapy for pediatric non-pineal supratentorial primitive neuroectodermal tumors. Int J Radiat Oncol Biol Phys. 2008 Dec 01; 72(5):1319-23. PMID: 18485615.
      View in: PubMed
    56. Khayal IS, Crawford FW, Saraswathy S, Lamborn K, Chang SM, Cha S, McKnight TR, Nelson SJ. Relationship between choline and apparent diffusion coefficient in patients with gliomas. J Magn Reson Imaging. 2008 Apr; 27(4):718-25. PMID: 18383265; PMCID: PMC3030277.
    57. Chang EF, Zada G, Kim S, Lamborn K, Quinones-Hinojosa A, Tyrrell JB, Wilson CB, Kunwar S. Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. J Neurosurg. 2008 Apr; 108(4):736-45. PMID: 18377253.
      View in: PubMed
    58. Smith JS, Chang EF, Lamborn K, Chang SM, Prados MD, Cha S, Tihan T, Vandenberg S, McDermott MW, Berger MS. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol. 2008 Mar 10; 26(8):1338-45. PMID: 18323558.
      View in: PubMed
    59. Lamborn K, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Fink KL, Junck L, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Hibberts J, Peterson PM, Prados MD. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol. 2008 Apr; 10(2):162-70. PMID: 18356283; PMCID: PMC2613818.
    60. Hashizume R, Ozawa T, Gryaznov SM, Bollen AW, Lamborn K, Frey WH, Deen DF. New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163. Neuro Oncol. 2008 Apr; 10(2):112-20. PMID: 18287341; PMCID: PMC2613813.
    61. Chang EF, Potts MB, Keles GE, Lamborn K, Chang SM, Barbaro NM, Berger MS. Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg. 2008 Feb; 108(2):227-35. PMID: 18240916.
      View in: PubMed
    62. Papavassiliou E, Rau G, Heath S, Abosch A, Barbaro NM, Larson PS, Lamborn K, Starr PA. Thalamic deep brain stimulation for essential tremor: relation of lead location to outcome. Neurosurgery. 2008 Feb; 62 Suppl 2:884-94. PMID: 18596419.
      View in: PubMed
    63. Kuhn JG, Chang SM, Wen PY, Cloughesy TF, Greenberg H, Schiff D, Conrad C, Fink KL, Robins HI, Mehta M, DeAngelis L, Raizer J, Hess K, Lamborn K, Dancey J, Prados MD. Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res. 2007 Dec 15; 13(24):7401-6. PMID: 18094423; PMCID: PMC4918812.
    64. Loghin ME, Prados MD, Wen P, Junck L, Lieberman F, Fine H, Fink KL, Metha M, Kuhn J, Lamborn K, Chang SM, Cloughesy T, DeAngelis LM, Robins IH, Aldape KD, Yung WK. Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study. Clin Cancer Res. 2007 Dec 01; 13(23):7133-8. PMID: 18056194; PMCID: PMC4802002.
    65. Schillaci O, DeNardo GL, DeNardo SJ, Goldstein DS, Kroger LA, O'Donnell RT, Lamborn K. Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma. Cancer Biother Radiopharm. 2007 Aug; 22(4):521-30. PMID: 17803447.
      View in: PubMed
    66. Chen AM, Chang S, Pouliot J, Sneed PK, Prados MD, Lamborn K, Malec MK, McDermott MW, Berger MS, Larson DA. Phase I trial of gross total resection, permanent iodine-125 brachytherapy, and hyperfractionated radiotherapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2007 Nov 01; 69(3):825-30. PMID: 17512132.
      View in: PubMed
    67. Wiencke JK, Zheng S, Jelluma N, Tihan T, Vandenberg S, Tamgüney T, Baumber R, Parsons R, Lamborn K, Berger MS, Wrensch MR, Haas-Kogan DA, Stokoe D. Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Neuro Oncol. 2007 Jul; 9(3):271-9. PMID: 17504928; PMCID: PMC1907411.
    68. Butowski N, Lamborn K, Berger MS, Prados MD, Chang SM. Historical controls for phase II surgically based trials requiring gross total resection of glioblastoma multiforme. J Neurooncol. 2007 Oct; 85(1):87-94. PMID: 17457513.
      View in: PubMed
    69. Chen JK, Hu LJ, Wang D, Lamborn K, Deen DF. Cytosine deaminase/5-fluorocytosine exposure induces bystander and radiosensitization effects in hypoxic glioblastoma cells in vitro. Int J Radiat Oncol Biol Phys. 2007 Apr 01; 67(5):1538-47. PMID: 17394949.
      View in: PubMed
    70. Smith JS, Parney IF, Lamborn K, McDermott MW, Sneed PK, Chang SM. Treatment for posterior fossa dissemination of primary supratentorial glioma. J Neurosurg. 2007 Apr; 106(4):567-74. PMID: 17432705.
      View in: PubMed
    71. McKnight TR, Lamborn K, Love TD, Berger MS, Chang S, Dillon WP, Bollen A, Nelson SJ. Correlation of magnetic resonance spectroscopic and growth characteristics within Grades II and III gliomas. J Neurosurg. 2007 Apr; 106(4):660-6. PMID: 17432719.
      View in: PubMed
    72. Entin-Meer M, Yang X, VandenBerg SR, Lamborn K, Nudelman A, Rephaeli A, Haas-Kogan DA. In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas. Neuro Oncol. 2007 Apr; 9(2):82-8. PMID: 17347490; PMCID: PMC1871664.
    73. Koo MS, Ozawa T, Santos RA, Lamborn K, Bollen AW, Deen DF, Kahl SB. Synthesis and comparative toxicology of a series of polyhedral borane anion-substituted tetraphenyl porphyrins. J Med Chem. 2007 Feb 22; 50(4):820-7. PMID: 17253677.
      View in: PubMed
    74. Yoo H, Baia GS, Smith JS, McDermott MW, Bollen AW, Vandenberg SR, Lamborn K, Lal A. Expression of the hypoxia marker carbonic anhydrase 9 is associated with anaplastic phenotypes in meningiomas. Clin Cancer Res. 2007 Jan 01; 13(1):68-75. PMID: 17200340.
      View in: PubMed
    75. Groves MD, Puduvalli VK, Chang SM, Conrad CA, Gilbert MR, Tremont-Lukats IW, Liu TJ, Peterson P, Schiff D, Cloughesy TF, Wen PY, Greenberg H, Abrey LE, DeAngelis LM, Hess KR, Lamborn K, Prados MD, Yung WK. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol. 2007 Feb; 81(3):271-7. PMID: 17031561.
      View in: PubMed
    76. Ozawa T, Faddegon BA, Hu LJ, Bollen AW, Lamborn K, Deen DF. Response of intracerebral human glioblastoma xenografts to multifraction radiation exposures. Int J Radiat Oncol Biol Phys. 2006 Sep 01; 66(1):263-70. PMID: 16904526.
      View in: PubMed
    77. Wen PY, Yung WK, Lamborn K, Dahia PL, Wang Y, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K, Gilbert M, Chang S, Junck L, Schiff D, Lieberman F, Fine HA, Mehta M, Robins HI, DeAngelis LM, Groves MD, Puduvalli VK, Levin V, Conrad C, Maher EA, Aldape K, Hayes M, Letvak L, Egorin MJ, Capdeville R, Kaplan R, Murgo AJ, Stiles C, Prados MD. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res. 2006 Aug 15; 12(16):4899-907. PMID: 16914578.
      View in: PubMed
    78. Cloughesy TF, Wen PY, Robins HI, Chang SM, Groves MD, Fink KL, Junck L, Schiff D, Abrey L, Gilbert MR, Lieberman F, Kuhn J, DeAngelis LM, Mehta M, Raizer JJ, Yung WK, Aldape K, Wright J, Lamborn K, Prados MD. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol. 2006 Aug 01; 24(22):3651-6. PMID: 16877733.
      View in: PubMed
    79. Keles GE, Chang EF, Lamborn K, Tihan T, Chang CJ, Chang SM, Berger MS. Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. J Neurosurg. 2006 Jul; 105(1):34-40. PMID: 16871879.
      View in: PubMed
    80. Wrensch M, Wiencke JK, Wiemels J, Miike R, Patoka J, Moghadassi M, McMillan A, Kelsey KT, Aldape K, Lamborn K, Parsa AT, Sison JD, Prados MD. Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. Cancer Res. 2006 Apr 15; 66(8):4531-41. PMID: 16618782.
      View in: PubMed
    81. Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Chang S, Nicholas MK, Schiff D, Greenberg H, Junck L, Fink K, Hess K, Kuhn J. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 2006 Apr; 8(2):189-93. PMID: 16533878; PMCID: PMC1871932.
    82. Mishra KK, Puri DR, Missett BT, Lamborn K, Prados MD, Berger MS, Banerjee A, Gupta N, Wara WM, Haas-Kogan DA. The role of up-front radiation therapy for incompletely resected pediatric WHO grade II low-grade gliomas. Neuro Oncol. 2006 Apr; 8(2):166-74. PMID: 16495375; PMCID: PMC1871938.
    83. Azinovic I, DeNardo GL, Lamborn K, Mirick G, Goldstein D, Bradt BM, DeNardo SJ. Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies. Cancer Immunol Immunother. 2006 Dec; 55(12):1451-8. PMID: 16496145.
      View in: PubMed
    84. Wrensch M, Rice T, Miike R, McMillan A, Lamborn K, Aldape K, Prados MD. Diagnostic, treatment, and demographic factors influencing survival in a population-based study of adult glioma patients in the San Francisco Bay Area. Neuro Oncol. 2006 Jan; 8(1):12-26. PMID: 16443944; PMCID: PMC1871921.
    85. Prados MD, Lamborn K, Chang S, Burton E, Butowski N, Malec M, Kapadia A, Rabbitt J, Page MS, Fedoroff A, Xie D, Kelley SK. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol. 2006 Jan; 8(1):67-78. PMID: 16443950; PMCID: PMC1871925.
    86. Misra A, Pellarin M, Hu L, Kunwar S, Perhouse M, Lamborn K, Deen DF, Feuerstein BG. Chromosome transfer experiments link regions on chromosome 7 to radiation resistance in human glioblastoma multiforme. Genes Chromosomes Cancer. 2006 Jan; 45(1):20-30. PMID: 16130123.
      View in: PubMed
    87. Miers L, DeNardo SJ, Lamborn K, DeNardo GL. Implantation of different malignant human cell lines in an athymic mouse does not alter success and growth rates of either xenograft. Cancer Biother Radiopharm. 2005 Dec; 20(6):614-9. PMID: 16398613.
      View in: PubMed
    88. Ozawa T, Britz GW, Kinder DH, Spence AM, VandenBerg S, Lamborn K, Deen DF, Berger MS. Bromophenol blue staining of tumors in a rat glioma model. Neurosurgery. 2005 Nov; 57(5):1041-7; discussion 1041-7. PMID: 16284574.
      View in: PubMed
    89. Lassman AB, Rossi MR, Raizer JJ, Razier JR, Abrey LE, Lieberman FS, Grefe CN, Lamborn K, Pao W, Shih AH, Kuhn JG, Wilson R, Nowak NJ, Cowell JK, DeAngelis LM, Wen P, Gilbert MR, Chang S, Yung WA, Prados M, Holland EC. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res. 2005 Nov 01; 11(21):7841-50. PMID: 16278407.
      View in: PubMed
    90. Lu Y, Jin H, Lamborn K. A design of phase II cancer trials using total and complete response endpoints. Stat Med. 2005 Oct 30; 24(20):3155-70. PMID: 16189806.
      View in: PubMed
    91. Haas-Kogan DA, Prados MD, Lamborn K, Tihan T, Berger MS, Stokoe D. Biomarkers to predict response to epidermal growth factor receptor inhibitors. Cell Cycle. 2005 Oct; 4(10):1369-72. PMID: 16177570.
      View in: PubMed
    92. Miers L, Lamborn K, Yuan A, Richman C, Natarajan A, DeNardo S, DeNardo G. Does paclitaxel (Taxol) given after (111)In-labeled monoclonal antibodies increase tumor-cumulated activity in epithelial cancers? Clin Cancer Res. 2005 Oct 01; 11(19 Pt 2):7158s-7163s. PMID: 16203816.
      View in: PubMed
    93. Chang SM, Reynolds SL, Butowski N, Lamborn K, Buckner JC, Kaplan RS, Bigner DD. GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials. Neuro Oncol. 2005 Oct; 7(4):425-34. PMID: 16212807; PMCID: PMC1871726.
    94. Cloughesy TF, Kuhn J, Robins HI, Abrey L, Wen P, Fink K, Lieberman FS, Mehta M, Chang S, Yung A, DeAngelis L, Schiff D, Junck L, Groves M, Paquette S, Wright J, Lamborn K, Sebti SM, Prados M. Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol. 2005 Sep 20; 23(27):6647-56. PMID: 16170172.
      View in: PubMed
    95. Ozawa T, Afzal J, Lamborn K, Bollen AW, Bauer WF, Koo MS, Kahl SB, Deen DF. Toxicity, biodistribution, and convection-enhanced delivery of the boronated porphyrin BOPP in the 9L intracerebral rat glioma model. Int J Radiat Oncol Biol Phys. 2005 Sep 01; 63(1):247-52. PMID: 16111595.
      View in: PubMed
    96. Richman CM, Denardo SJ, O'Donnell RT, Yuan A, Shen S, Goldstein DS, Tuscano JM, Wun T, Chew HK, Lara PN, Kukis DL, Natarajan A, Meares CF, Lamborn K, DeNardo GL. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody. Clin Cancer Res. 2005 Aug 15; 11(16):5920-7. PMID: 16115934.
      View in: PubMed
    97. Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, De Angelis L, Raizer J, Hess K, Aldape K, Lamborn K, Kuhn J, Dancey J, Prados MD. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs. 2005 Aug; 23(4):357-61. PMID: 16012795.
      View in: PubMed
    98. Gomez DR, Missett BT, Wara WM, Lamborn K, Prados MD, Chang S, Berger MS, Haas-Kogan DA. High failure rate in spinal ependymomas with long-term follow-up. Neuro Oncol. 2005 Jul; 7(3):254-9. PMID: 16053700; PMCID: PMC1871913.
    99. Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND, Baumber R, Lamborn K, Kapadia A, Malec M, Berger MS, Stokoe D. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst. 2005 Jun 15; 97(12):880-7. PMID: 15956649.
      View in: PubMed
    100. Chen JK, Hu LJ, Wang J, Lamborn K, Kong EL, Deen DF. Hypoxia-induced BAX overexpression and radiation killing of hypoxic glioblastoma cells. Radiat Res. 2005 Jun; 163(6):644-53. PMID: 15913396.
      View in: PubMed
    101. Quiñones-Hinojosa A, Lyon R, Zada G, Lamborn K, Gupta N, Parsa AT, McDermott MW, Weinstein PR. Changes in transcranial motor evoked potentials during intramedullary spinal cord tumor resection correlate with postoperative motor function. Neurosurgery. 2005 May; 56(5):982-93; discussion 982-93. PMID: 15854246.
      View in: PubMed
    102. Ozawa T, Hu JL, Hu LJ, Kong EL, Bollen AW, Lamborn K, Deen DF. Functionality of hypoxia-induced BAX expression in a human glioblastoma xenograft model. Cancer Gene Ther. 2005 May; 12(5):449-55. PMID: 15706354.
      View in: PubMed
    103. Misra A, Pellarin M, Nigro J, Smirnov I, Moore D, Lamborn K, Pinkel D, Albertson DG, Feuerstein BG. Array comparative genomic hybridization identifies genetic subgroups in grade 4 human astrocytoma. Clin Cancer Res. 2005 Apr 15; 11(8):2907-18. PMID: 15837741.
      View in: PubMed
    104. Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, Nicholas MK, Lamborn K, Berger MS, Botstein D, Brown PO, Israel MA. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A. 2005 Apr 19; 102(16):5814-9. PMID: 15827123; PMCID: PMC556127.
    105. Parsa AT, Wachhorst S, Lamborn K, Prados MD, McDermott MW, Berger MS, Chang SM. Prognostic significance of intracranial dissemination of glioblastoma multiforme in adults. J Neurosurg. 2005 Apr; 102(4):622-8. PMID: 15871503.
      View in: PubMed
    106. Butowski N, Prados MD, Lamborn K, Larson DA, Sneed PK, Wara WM, Malec M, Rabbitt J, Page M, Chang SM. A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma. Int J Radiat Oncol Biol Phys. 2005 Apr 01; 61(5):1454-9. PMID: 15817350.
      View in: PubMed
    107. Wang D, Ruan H, Hu L, Lamborn K, Kong EL, Rehemtulla A, Deen DF. Development of a hypoxia-inducible cytosine deaminase expression vector for gene-directed prodrug cancer therapy. Cancer Gene Ther. 2005 Mar; 12(3):276-83. PMID: 15650767.
      View in: PubMed
    108. Hammer GD, Tyrrell JB, Lamborn K, Applebury CB, Hannegan ET, Bell S, Rahl R, Lu A, Wilson CB. Transsphenoidal microsurgery for Cushing's disease: initial outcome and long-term results. J Clin Endocrinol Metab. 2004 Dec; 89(12):6348-57. PMID: 15579802.
      View in: PubMed
    109. Chang SM, Lamborn K, Malec M, Larson D, Wara W, Sneed P, Rabbitt J, Page M, Nicholas MK, Prados MD. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2004 Oct 01; 60(2):353-7. PMID: 15380566.
      View in: PubMed
    110. Ozawa T, Santos RA, Lamborn K, Bauer WF, Koo MS, Kahl SB, Deen DF. In vivo evaluation of the boronated porphyrin TABP-1 in U-87 MG intracerebral human glioblastoma xenografts. Mol Pharm. 2004 Sep-Oct; 1(5):368-74. PMID: 16026007.
      View in: PubMed
    111. Lamborn K, Chang SM, Prados MD. Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol. 2004 Jul; 6(3):227-35. PMID: 15279715; PMCID: PMC1871999.
    112. Ozawa T, Gryaznov SM, Hu LJ, Pongracz K, Santos RA, Bollen AW, Lamborn K, Deen DF. Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts. Neuro Oncol. 2004 Jul; 6(3):218-26. PMID: 15279714; PMCID: PMC1871998.
    113. Papavassiliou E, Rau G, Heath S, Abosch A, Barbaro NM, Larson PS, Lamborn K, Starr PA. Thalamic deep brain stimulation for essential tremor: relation of lead location to outcome. Neurosurgery. 2004 May; 54(5):1120-29; discussion 1129-30. PMID: 15113466.
      View in: PubMed
    114. Larson DA, Suplica JM, Chang SM, Lamborn K, McDermott MW, Sneed PK, Prados MD, Wara WM, Nicholas MK, Berger MS. Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme. Neuro Oncol. 2004 Apr; 6(2):119-26. PMID: 15134626; PMCID: PMC1871978.
    115. Keles GE, Lundin DA, Lamborn K, Chang EF, Ojemann G, Berger MS. Intraoperative subcortical stimulation mapping for hemispherical perirolandic gliomas located within or adjacent to the descending motor pathways: evaluation of morbidity and assessment of functional outcome in 294 patients. J Neurosurg. 2004 Mar; 100(3):369-75. PMID: 15035270.
      View in: PubMed
    116. Chang SM, Theodosopoulos P, Lamborn K, Malec M, Rabbitt J, Page M, Prados MD. Temozolomide in the treatment of recurrent malignant glioma. Cancer. 2004 Feb 01; 100(3):605-11. PMID: 14745879.
      View in: PubMed
    117. Keles GE, Lamborn K, Chang SM, Prados MD, Berger MS. Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy. J Neurosurg. 2004 Jan; 100(1):41-6. PMID: 14743910.
      View in: PubMed
    118. Auguste KI, Quinones-Hinojosa A, Gadkary C, Zada G, Lamborn K, Berger MS. Incidence of venous thromboembolism in patients undergoing craniotomy and motor mapping for glioma without intraoperative mechanical prophylaxis to the contralateral leg. J Neurosurg. 2003 Oct; 99(4):680-4. PMID: 14567603.
      View in: PubMed
    119. DeNardo SJ, Yao Z, Lam KS, Song A, Burke PA, Mirick GR, Lamborn K, O'Donnell RT, DeNardo GL. Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma-bearing mice. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 2):3854S-64S. PMID: 14506183.
      View in: PubMed
    120. Keles GE, Lamborn K, Berger MS. Coregistration accuracy and detection of brain shift using intraoperative sononavigation during resection of hemispheric tumors. Neurosurgery. 2003 Sep; 53(3):556-62; discussion 562-4. PMID: 12943572.
      View in: PubMed
    121. DeNardo GL, DeNardo SJ, Peterson JJ, Miers LA, Lam KS, Hartmann-Siantar C, Lamborn K. Preclinical evaluation of cathepsin-degradable peptide linkers for radioimmunoconjugates. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 2):3865S-72S. PMID: 14506184.
      View in: PubMed
    122. DeNardo SJ, DeNardo GL, Yuan A, Richman CM, O'Donnell RT, Lara PN, Kukis DL, Natarajan A, Lamborn K, Jacobs F, Siantar CL. Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 2):3938S-44S. PMID: 14506192.
      View in: PubMed
    123. Winthrop MD, DeNardo SJ, Albrecht H, Mirick GR, Kroger LA, Lamborn K, Venclovas C, Colvin ME, Burke PA, DeNardo GL. Selection and characterization of anti-MUC-1 scFvs intended for targeted therapy. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 2):3845S-53S. PMID: 14506182.
      View in: PubMed
    124. DeNardo GL, Mirick GR, Kroger LA, Bradt BM, Lamborn K, DeNardo SJ. Characterization of human IgG antimouse antibody in patients with B-cell malignancies. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 2):4013S-21S. PMID: 14506202.
      View in: PubMed
    125. Vates GE, Chang S, Lamborn K, Prados M, Berger MS. Gliomatosis cerebri: a review of 22 cases. Neurosurgery. 2003 Aug; 53(2):261-71; discussion 271. PMID: 12925240.
      View in: PubMed
    126. Wang J, Klem J, Wyrick JB, Ozawa T, Cunningham E, Golinveaux J, Allen MJ, Lamborn K, Deen DF. Detection of hypoxia in human brain tumor xenografts using a modified comet assay. Neoplasia. 2003 Jul-Aug; 5(4):288-96. PMID: 14511400; PMCID: PMC1502416.
    127. Haas-Kogan DA, Missett BT, Wara WM, Donaldson SS, Lamborn K, Prados MD, Fisher PG, Huhn SL, Fisch BM, Berger MS, Le QT. Radiation therapy for intracranial germ cell tumors. Int J Radiat Oncol Biol Phys. 2003 Jun 01; 56(2):511-8. PMID: 12738328.
      View in: PubMed
    128. Schmidt MH, Berger MS, Lamborn K, Aldape K, McDermott MW, Prados MD, Chang SM. Repeated operations for infiltrative low-grade gliomas without intervening therapy. J Neurosurg. 2003 Jun; 98(6):1165-9. PMID: 12816258.
      View in: PubMed
    129. Hirose Y, Aldape KD, Chang S, Lamborn K, Berger MS, Feuerstein BG. Grade II astrocytomas are subgrouped by chromosome aberrations. Cancer Genet Cytogenet. 2003 Apr 01; 142(1):1-7. PMID: 12660025.
      View in: PubMed
    130. Tuscano JM, O'Donnell RT, Miers LA, Kroger LA, Kukis DL, Lamborn K, Tedder TF, DeNardo GL. Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts. Blood. 2003 May 01; 101(9):3641-7. PMID: 12511412.
      View in: PubMed
    131. Larson DA, Prados M, Lamborn K, Smith V, Sneed PK, Chang S, Nicholas KM, Wara WM, Devriendt D, Kunwar S, Berger M, McDermott MW. Phase II study of high central dose Gamma Knife radiosurgery and marimastat in patients with recurrent malignant glioma. Int J Radiat Oncol Biol Phys. 2002 Dec 01; 54(5):1397-404. PMID: 12459362.
      View in: PubMed
    132. Burton EC, Lamborn K, Feuerstein BG, Prados M, Scott J, Forsyth P, Passe S, Jenkins RB, Aldape KD. Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma. Cancer Res. 2002 Nov 01; 62(21):6205-10. PMID: 12414648.
      View in: PubMed
    133. Zardo G, Tiirikainen MI, Hong C, Misra A, Feuerstein BG, Volik S, Collins CC, Lamborn K, Bollen A, Pinkel D, Albertson DG, Costello JF. Integrated genomic and epigenomic analyses pinpoint biallelic gene inactivation in tumors. Nat Genet. 2002 Nov; 32(3):453-8. PMID: 12355068.
      View in: PubMed
    134. Theodosopoulos PV, Marco E, Applebury C, Lamborn K, Wilson CB. Predictive model for pain recurrence after posterior fossa surgery for trigeminal neuralgia. Arch Neurol. 2002 Aug; 59(8):1297-302. PMID: 12164727.
      View in: PubMed
    135. Burke PA, DeNardo SJ, Miers LA, Lamborn K, Matzku S, DeNardo GL. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res. 2002 Aug 01; 62(15):4263-72. PMID: 12154028.
      View in: PubMed
    136. Donaldson SS, Hudson MM, Lamborn K, Link MP, Kun L, Billett AL, Marcus KC, Hurwitz CA, Young JA, Tarbell NJ, Weinstein HJ. VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: results of a prospective clinical trial. J Clin Oncol. 2002 Jul 15; 20(14):3081-7. PMID: 12118021.
      View in: PubMed
    137. Kuriyama H, Lamborn K, O'Fallon JR, Iturria N, Sebo T, Schaefer PL, Scheithauer BW, Buckner JC, Kuriyama N, Jenkins RB, Israel MA. Prognostic significance of an apoptotic index and apoptosis/proliferation ratio for patients with high-grade astrocytomas. Neuro Oncol. 2002 07; 4(3):179-86. PMID: 12084348; PMCID: PMC1920640.
    138. Chun JY, McDermott MW, Lamborn K, Wilson CB, Higashida R, Berger MS. Delayed surgical resection reduces intraoperative blood loss for embolized meningiomas. Neurosurgery. 2002 Jun; 50(6):1231-5; discussion 1235-7. PMID: 12015840.
      View in: PubMed
    139. Ermoian RP, Furniss CS, Lamborn K, Basila D, Berger MS, Gottschalk AR, Nicholas MK, Stokoe D, Haas-Kogan DA. Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. Clin Cancer Res. 2002 May; 8(5):1100-6. PMID: 12006525.
      View in: PubMed
    140. O'Donnell RT, DeNardo SJ, Miers LA, Lamborn K, Kukis DL, DeNardo GL, Meyers FJ. Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6. Prostate. 2002 Jan 01; 50(1):27-37. PMID: 11757033.
      View in: PubMed
    141. Ozawa T, Wang J, Hu LJ, Bollen AW, Lamborn K, Deen DF. Growth of human glioblastomas as xenografts in the brains of athymic rats. In Vivo. 2002 Jan-Feb; 16(1):55-60. PMID: 11980362.
      View in: PubMed
    142. Burton EC, Lamborn K, Forsyth P, Scott J, O'Campo J, Uyehara-Lock J, Prados M, Berger M, Passe S, Uhm J, O'Neill BP, Jenkins RB, Aldape KD. Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. Clin Cancer Res. 2002 Jan; 8(1):180-7. PMID: 11801556.
      View in: PubMed